Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3 · 48 sites
Search the registry
2,585 studies found
Phase 3 · 48 sites
Phase 1 / Phase 2 · 1 site
Phase 2 · 1 site
Phase 2 · 2 sites
Phase 2 · 2 sites
Potential match only. Final eligibility is determined by the study team.